1. Value in Health Regional Issues
How Data Packages Lacking Phase III Pivotal Trial Data Can Support Regulatory Approval and Reimbursement for Oncologics in Australia 
Richard Macaulay, PhD, Mohammad Kashif Siddiqui, MPharm, Samuel Stoddart, PhD 
Value in Health Regional Issues 
Volume 6, Pages (May 2015)
DOI: /j.vhri
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Timeline of oncology appraisals by the PBAC on the basis of a pivotal trial data package lacking comparative phase III data. ALL, acute lymphoblastic leukemia; ASM, aggressive systemic mastocytosis; CML, chronic myeloid leukemia; CRC, colorectal cancer; DMSP, dermatofibrosarcoma protuberans; GBM, glioblastoma; HES-CEL, hypereosinophilic syndrome-chronic eosinophilic leukemia; LYG, life-year gained; PBAC, Pharmaceutical Benefits Advisory Committee; MDS/MPD, myelodysplastic/myeloproliferative diseases; sALCL, systemic anaplastic large cell lymphoma.
Value in Health Regional Issues 2015 6, DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions